Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignanciesJordan Gauthier, Cameron J. Turtle, Ryan D. Cassaday et al.|Blood|2020Cited by 217
Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansionSalvatore Fiorenza, Cameron J. Turtle, Ye Zheng et al.|Nature Communications|2024Cited by 10
Targeting the membrane-proximal C2-set domain of CD33 for improved CAR T cell therapySalvatore Fiorenza, Roland B. Walter, Sheryl Y.T. Lim et al.|Molecular Therapy Oncology|2024Cited by 9
Histone Methylation Mark Analyses Distinguish Carts Manufactured from Distinct Sources and Uncover Novel Transcription Factors Associated with In Vivo Function of Carts after Infusion into DLBCL Patients That Are Not Identified By RNA-SeqSalvatore Fiorenza, Cameron J. Turtle, Ye Zheng et al.|Blood|2023Cited by 0
Serial Stimulation of CAR-T Cells Manufactured from Different T Cell Subsets Reveals Distinct Patterns of Dysfunction That Are Dissociated from Immunophenotypic ExhaustionSalvatore Fiorenza, Cameron J. Turtle, Tinh-Doan Phi et al.|Transplantation and Cellular Therapy|2022Cited by 0